H1B Report
Side-by-side comparison

NOVARTIS PHARMACEUTICALS CORPORATION vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
NOVARTIS PHARMACEUTICALS CORPORATION
NJRank #FEIN 22-1857084
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricNOVARTIS PHARMACEUTICALS CORPORATIONWIPRO LIMITED
Total filings90972,392
Certified %96.04%91.61%
Denied %0.55%0.37%
Withdrawn %2.09%1.37%
Cert-withdrawn %1.32%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNJNJ

Outcomes — NOVARTIS PHARMACEUTICALS CORPORATION

DOL case-status mix.

Outcome breakdown: Certified 96.0%, Cert-withdrawn 1.3%, Withdrawn 2.1%, Denied 0.6%
Outcome breakdown
OutcomeShare
Certified96.0%
Cert-withdrawn1.3%
Withdrawn2.1%
Denied0.6%
Certified96.0%
Cert-withdrawn1.3%
Withdrawn2.1%
Denied0.6%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

NOVARTIS PHARMACEUTICALS CORPORATION
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201052
FY201145
FY201260
FY201344
FY201461
FY201548
FY201663
FY201754
FY201840
FY201960
FY202028
FY202143
FY202219
FY202344
FY202491
FY2025114
FY202643
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — NOVARTIS PHARMACEUTICALS CORPORATION

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.